Influence of obesity and metabolic dysfunction on the endothelial control in the coronary circulation

Eric J Belin de Chantemele1, David W Stepp

  • 1Department of Physiology and the Vascular Biology Center, Georgia Health Sciences University, Augusta, GA 30912, USA,

Insights

Obesity and diabetes worsen coronary circulation by impairing endothelial function, a key factor in heart disease. Understanding this link is crucial for managing cardiovascular risks in these metabolic conditions.

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Diseases
  • Vascular Biology

Background:

  • Coronary circulation diseases are a leading cause of death in Western societies.
  • Obesity and metabolic dysfunction are significant risk factors for coronary disease.
  • The impact of obesity and diabetes on coronary vasculature is not fully understood.

Purpose of the Study:

  • To review the pathological impact of obesity and diabetes on coronary function.
  • To examine how obesity and diabetes affect endothelial function.
  • To explore the role of the vascular endothelium in coronary health.

Main Methods:

  • Review of existing literature on obesity, diabetes, and coronary function.
  • Analysis of the role of endothelial dysfunction in metabolic diseases.
  • Synthesis of current research on the interplay between metabolic factors and vascular health.

Main Results:

  • Obesity and diabetes significantly contribute to endothelial dysfunction.
  • Endothelial dysfunction is a critical pathway linking metabolic disorders to coronary disease.
  • Impaired endothelial function affects hemostasis, vascular tone, and atherosclerosis progression.

Conclusions:

  • Obesity and diabetes pose significant threats to coronary circulation, primarily through endothelial dysfunction.
  • Further research is needed to fully elucidate the mechanisms linking these conditions to cardiovascular disease.
  • Targeting endothelial function may offer therapeutic strategies for patients with obesity and diabetes.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...